Most Kids With the Flu Miss Out on Antiviral Tamiflu
TUESDAY, Nov. 14, 2023 -- Children stricken with influenza aren ’t receiving the flu-busting antiviral drug Tamiflu even though it’s recommended for them, a new study says.Three of five children with the flu aren’t prescribed Tamiflu,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 14, 2023 Category: General Medicine Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Is It Flu, COVID-19, or RSV? How to Navigate the New World of At-Home Testing
Before COVID-19, figuring out whether a sore throat, fever, and runny nose were caused by a cold, flu, or strep wasn’t a top priority. You either powered through, knowing you’d be miserable for a few days but would probably feel better soon or you visited the doctor’s office, urgent care, or emergency room where you might get a test to figure out which virus or bacteria was behind your misery, and maybe a prescription to treat it. But even doctors often don’t order tests, preferring instead to make diagnoses based on symptoms.
[time-brightcove not-tgx=”true”]
During the pandemic, how...
Source: TIME: Health - September 25, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
How to Avoid the Tripledemic of Respiratory Diseases This Winter
[time-brightcove not-tgx=”true”]
“Tripledemic“ jumped into our vocabulary and lives last year, referring to the winter surges of three respiratory viruses—RSV (respiratory syncytial virus), flu (influenza), and COVID-19. The tripledemic of 2022 infected millions, overwhelmed hospital systems, and killed more than 100,000 people in the U.S. over the 4-month peak span of these viruses.
As much as we hoped that respiratory illness would fade with the COVID-19 public health emergency ending, we must recognize that these viruses will continue to impact us for years. As the school year b...
Source: TIME: Health - September 16, 2023 Category: Consumer Health News Authors: Scott A. Rivkees Tags: Uncategorized freelance Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news
Oseltamivir Not Linked to Reduced Risk for Flu Hospitalization
WEDNESDAY, June 14, 2023 -- For outpatients with influenza infection, oseltamivir is not associated with a reduced risk for hospitalization, according to a review published online June 12 in JAMA Internal Medicine.
Ryan Hanula, from the McGill... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2023 Category: Pharmaceuticals Source Type: news
Tamiflu a Bust for Preventing Flu Admissions, Meta-Analysis Finds
(MedPage Today) -- Oseltamivir (Tamiflu) has not panned out for reducing the risk of influenza hospitalization, according to a large meta-analysis.
Among over 6,000 flu patients across 15 studies, the 0.14-percentage point difference in hospitalization... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - June 12, 2023 Category: Infectious Diseases Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of Polivy (first-line treatment for an aggressive form of blood cancer)EU approva...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
Basel, 26 April 2023As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of Polivy (first-line treatment for an aggressive form of blo...
Source: Roche Media News - April 26, 2023 Category: Pharmaceuticals Source Type: news
First combination home test for flu and covid cleared by the FDA
The Food and Drug Administration on Friday authorized the first combination test for the flu and the coronavirus that is fully performed at home, giving consumers a convenient way to determine which pathogen may be causing their respiratory illnesses. The agency granted emergency use authorization…#luciracovid19flutest #rsv #fda #lucira #tamiflu #jeffshuren #shiraidoron #tuftsmedicalcenter #boston #doron (Source: Reuters: Health)
Source: Reuters: Health - February 25, 2023 Category: Consumer Health News Source Type: news
Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster thanoseltamivirSingle-doseXofluza helps reduce the societal burden of influenza by helping patients recover quickly and by preventing infection in individuals following contact with someone with the virusBasel, 12 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC...
Source: Roche Investor Update - January 12, 2023 Category: Pharmaceuticals Source Type: news
Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza is the first influenza antiviral with a new mechanism of action in almost 20 years, stopping viral replication faster thanoseltamivirSingle-doseXofluza helps reduce the societal burden of influenza by helping patients recover quickly and by preventing infection in individuals following contact with someone with the virusBasel, 12 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC...
Source: Roche Media News - January 12, 2023 Category: Pharmaceuticals Source Type: news
U.S. Releases Tamiflu Stockpiles —Here’s Why Demand Is Surging
The U.S. Department of Health and Human Services announced Wednesday it will allow states to access Tamiflu doses from the national stockpile to meet surging demand, as the U.S. faces a severe and early flu season. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 22, 2022 Category: Pharmaceuticals Tags: Business /business Healthcare /healthcare Source Type: news
